Covid-19 roundup: UK pulls out of bil­lion-dol­lar vac­cine sup­ply deal as na­tion em­braces mix-and-match boost­er ap­proach

A vac­cine agree­ment be­tween the UK and French biotech Val­ne­va worth $1.65 bil­lion has been aban­doned af­ter the coun­try says terms of the deal were not met.

Val­ne­va’s vac­cine can­di­date us­es an in­ac­ti­vat­ed virus to in­voke an im­mune re­sponse. While that may pro­vide greater cov­er­age against the virus, it can al­so cause a longer man­u­fac­tur­ing timetable. The com­pa­ny an­nounced that Phase III re­sults for VLA2001 were ex­pect­ed in ear­ly Q4 2021, and will be a part of the can­di­date’s sub­mis­sion to the MHRA for ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER